Journal List > J Korean Soc Menopause > v.17(3) > 1052063

TOOLS
Cho and Park: The National Use of Hormonal Therapy in Postmenopausal Women in 2010
Original Article
The Journal of Korean Society of Menopause

The Journal of Korean Society of Menopause 2011; 17(3): 150-154.

Published online: 31 December 2011

DOI: https://doi.org/10.6118/jksm.2011.17.3.150

The National Use of Hormonal Therapy in Postmenopausal Women in 2010

Moon Kyoung Cho, M.D.1, Hyoung Moo Park, M.D.2

1Department of Obstetrics and Gynecology, Chonnam National University Medical School, Gwangju, Seoul, Korea.

2Department of Obstetrics and Gynecology, College of Medicine, Chung-Ang University, Seoul, Korea.

Corresponding author (hmpark@hananet.net)

Received 14 July 2011       Accepted 23 August 2011

Copyright © 2011 by The Korean Society of Menopause

Abstract

Objectives

To analyze the domestic consumption of postmenopausal hormonal medicine in the year 2010 and compare it with those since 2002.

Methods

Data from Intercontinental Marketing Services were used to analyze the consumption of hormonal medicine in the year 2010. Total hormonal medicines consisted of estrogen (ET), estrogen+progestogen (EPT), and Tibolone. We compared the respective consumption of hormonal medicines in the year 2010 with those since 2002. The percentage and frequency of usage of ET, ET/EPT, and tibolone in the year 2010 were also estimated.

Results

We found that 4.5% of women over 50 years of age had taken the postmenopausal hormonal medicine in the year 2010. The usage rate of each medicine showed 60% for ET/EPT compound, and 40% for Tibolone. The usage of postmenopausal hormonal medicine in 2010 increased by 7% compared to the previous year reaching 3.81 billion Korean won. There was 9% increase in the use of ET/EPT compound, and 4% increase in Tibolone.

Conclusion

The total consumption of postmenopausal hormonal medicine was markedly decreased between 2002 and 2007. Since 2007, however, it has been steadily increasing from 3.01 billion to more than 3.81 billion Korea won in 2010, which maybe due to the reappraisal of the WHI study results, the change of doctor's recognition, and the increased consumption of Tibolone. When initiating postmenopausal hormone replacement therapy, the risk-benefit of hormonal therapy should be thoroughly explored.

Keywords: Consumption, Hormone therapy, Postmenopause, Women

Figures and Tables

Fig. 1
The use of estrogen therapy (ET)/estrogen-progestogen therapy (EPT), Tibolone, and total postmenopausal hormonal medicine in Korea in 2009 and 2010. KRW: Korean won.
jksm-17-150-g001
Table 1
The percentage of costs for usage of estrogen therapy, estrogen therapy/estrogen-progestogen therapy, and Tibolone in 2010 in Korea
jksm-17-150-i001

ET: estrogen therapy, EPT: estrogen-progestogen therapy, KRW: Korean won

References

1. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004. 291:47–53.
2. Kim JY, Sang JH, Park HM. The change of hormone therapy in postmenopausal women in Korea before and after women's health initiative study: 2000~2009. Korean J Obstet Gynecol. 2010. 53:1110–1117.
3. Sturdee DW, Pines A, Archer DF, Baber RJ, Barlow D, Birkhauser MH, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011. 14:302–320.
4. Korea National Statistical Office. Population Projections for Korea: 2005~2050. 2006. Daejeon: Korea National Statistical Office.
5. Blumel JE, Chedraui P, Baron G, Belzares E, Bencosme A, Calle A, et al. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women. Menopause. 2011. 18:778–785.
6. Sang JH, Park HM. The National use of antiosteoporosis medication in 2009. J Korean Soc Menopause. 2010. 16:170–175.
7. Phillips LS, Langer RD. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril. 2005. 83:558–566.
8. Birkhauser MH, Reinecke I. Current trends in hormone replacement therapy: perceptions and usage. Climacteric. 2008. 11:192–200.
9. Andersson K, Mattsson LA, Milsom I. Use of hormone replacement therapy. Lancet. 1996. 348:1521.
10. Huang KE, Baber R. Updated clinical recommendations for the use of tibolone in Asian women. Climacteric. 2010. 13:317–327.
TOOLS
Similar articles